Week #4 FDA IGNORES PATIENTS LIKE STEPHEN STUDY — CareToLive Loses Another Member — Part II
April 22nd, 2008 | Posted by CTLCare To Live is very saddened by the loss of member Stephen H. Study. It is over a year since Provenge was voted 17-0 safe and 13-4 substantial evidence of efficacy by an FDA panel of experts. We are continuing our efforts on behalf of our have many prostate cancer sufferers desperately awaiting the approval of Provenge before it is too late for them. Here is week #4 of our ad campaign. Come on FDA. APPROVE PROVENGE NOW!!!!
Week #4 Color Ad Read and Print caretoliverockvillegazette4ad-part-2web.pdf
Week #4 Black & White Ad Read and Print caretoliverockvillegazette4ad-part-2bw.pdf
Next week, Week #5, we will place our ad in the Chevy Chase/Bethesda Gazette as we continue to raise awareness throughout the Maryland area as to the debacle that took place at the FDA in Rockville.
Popularity: 15%
Tags: Brachytherapy, Cancer Vaccine, Care To Live, CareToLive, commissioner Andrew Von Eschenbach, Dendreon, FDA, foia, Freedom of Information Act, Howard Scher, Immunotherapy, maha hussain, Michael Milken, Prostate Cancer, Prostate Gland, Prostatectomy, provenge, Richard Pazdur, Robotic Surgery, Thomas R Fleming

April 22nd, 2008 at 9:39 pm
[…] post by CTL delivered by Medtrials and […]